Survival remains poor for T-cell prolymphocytic leukemia, though treatment in recent years, associated with access to novel therapies, and management at academic medical centers is associated with improved outcomes. There remains a critical need to improve the available treatment options for this population, and access to specialized academic medical centers, comprehensive supportive care, clinical trials, and early palliative care remains essential for T-PLL patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ajh.27205 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!